14 Pharmaceuticals Stocks to Sell Now

14 Pharmaceuticals Stocks to Sell Now

The overall ratings of 14 Pharmaceuticals stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Taro Pharmaceutical Industries Ltd. (TARO) is having a tough week. The company’s rating falls from a C to a D. Taro Pharmaceutical Industries Ltd. is engaged in developing, manufacturing, and marketing prescription and over-the-counter pharmaceutical products, as well as active pharmaceutical ingredients in the United States, Canada and Israel. For more information, get Portfolio Grader’s complete analysis of TARO stock.

This is a rough week for Novo Nordisk A/S Sponsored ADR Class B (NVO). The company’s rating falls to F from the previous week’s D. Novo Nordisk A/S Sponsored ADR Class B develops, produces, and markets pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of NVO stock.

Slipping from a B to a D rating, Medicines Company (MDCO) takes a hit this week. Medicines Company develops products that improve specialized care. The company also gets F’s in sales growth and return on equity. For more information, get Portfolio Grader’s complete analysis of MDCO stock.

Astrazeneca PLC Sponsored ADR’s (AZN) rating weakens this week, dropping to a D versus last week’s C. Astrazeneca PLC Sponsored ADR is a biopharmaceutical company focused on therapy related to cardiovascular health, gastrointestinal health, infection, neuroscience, oncology and respiratory health, and inflammation. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of AZN stock.

Lannett Company, Inc. (LCI) slips from a C to a D this week. Lannett Company, Inc. manufactures and distributes pharmaceutical products under its own trade name and under generic names. The company also gets F’s in operating margin growth, earnings growth, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of LCI stock.

Flamel Technologies SA Sponsored ADR (FLML) declines this week from a D to a F. Flamel Technologies SA Sponsored ADR develops polymer technologies for applications such as drug delivery, biomaterials, and agrochemicals. The company also gets F’s in sales growth, earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of FLML stock.

Flex Pharma, Inc. (FLKS) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of FLKS stock.

This week, Zogenix, Inc. (ZGNX) drops from a D to a F rating. Zogenix, Inc. is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ZGNX stock.

Juniper Pharmaceuticals, Inc. (JNP) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in operating margin growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of JNP stock.

This week, Aradigm Corporation’s (ARDM) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in sales growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARDM stock.

Lipocine, Inc. (LPCN) experiences a ratings drop this week, going from last week’s D to a F. Lipocine, Inc. is engaged in the development of pharmaceutical products in the areas of men’’s and women’’s health. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of LPCN stock.

This week, EyeGate Pharmaceuticals, Inc.’s (EYEG) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of EYEG stock.

DURECT Corporation’s (DRRX) rating weakens this week, dropping to a F versus last week’s D. DURECT Corporation is a specialty pharmaceutical company that develops pharmaceutical systems technologies based on its proprietary drug delivery technology platforms. The company also gets F’s in sales growth, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of DRRX stock.

VIVUS, Inc. (VVUS) is having a tough week. The company’s rating falls from a C to a D. VIVUS, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. The company also gets F’s in sales growth, earnings revisions, and free cash flow. For more information, get Portfolio Grader’s complete analysis of VVUS stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/09/14-pharmaceuticals-stocks-to-sell-now/.

©2019 InvestorPlace Media, LLC